MD lawrence i karsh

All Stories

1. 
   Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

   Article • November 2025, American Association for Cancer Research (AACR)

   Helen M Wilfehrt, MD lawrence i karsh

2. 
   Supplementary Fig. 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

   Article • November 2025, American Association for Cancer Research (AACR)

   Helen M Wilfehrt, MD lawrence i karsh

3. 
   Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

   Article • November 2025, American Association for Cancer Research (AACR)

   Helen M Wilfehrt, MD lawrence i karsh

4. 
   Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

   Article • November 2025, American Association for Cancer Research (AACR)

   Helen M Wilfehrt, MD lawrence i karsh

5. 
   Metastatic Castration-Resistant Prostate Cancer: 14-Year Real-World Sipuleucel-T Outcomes in Urology

   Article • August 2025, Springer Science + Business Media

   MD lawrence i karsh

6. 
   Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS)

   Article • Prostate Cancer and Prostatic Diseases, December 2024, Springer Science + Business Media

   MD lawrence i karsh

7. 
   Data from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

   Article • September 2024, American Association for Cancer Research (AACR)

   MD lawrence i karsh, Helen M Wilfehrt

8. 
   Data from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

   Article • September 2024, American Association for Cancer Research (AACR)

   MD lawrence i karsh, Helen M Wilfehrt

9. 
   Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

   Article • September 2024, American Association for Cancer Research (AACR)

   MD lawrence i karsh, Helen M Wilfehrt

10. 
    Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • September 2024, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

11. 
    Supplementary Fig. 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • September 2024, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

12. 
    Supplementary Fig. 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • September 2024, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

13. 
    Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • September 2024, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

14. 
    Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • September 2024, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

15. 
    Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • September 2024, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

16. 
    Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • September 2024, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

17. 
    Data from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

18. 
    Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

19. 
    Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

20. 
    Supplementary Fig. 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

21. 
    Supplementary Fig. 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

22. 
    Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

23. 
    Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

24. 
    Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

25. 
    Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • July 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

26. 
    Data from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

27. 
    Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

28. 
    Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

29. 
    Supplementary Fig. 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

30. 
    Supplementary Fig. 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

31. 
    Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

32. 
    Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

33. 
    Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

34. 
    Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • May 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

35. 
    Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

    Article • Clinical Cancer Research, April 2023, American Association for Cancer Research (AACR)

    MD lawrence i karsh, Helen M Wilfehrt

36. 
    Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design

    Article • Future Oncology, January 2022, Taylor & Francis

    MD lawrence i karsh

37. 
    Optimizing the management of castration‐resistant prostate cancer patients: A practical guide for clinicians

    Article • The Prostate, August 2020, Wiley

    MD lawrence i karsh

38. 
    Intramuscular depot formulations of leuprolide acetate suppress testosterone <20 ng/dL threshold

    Article • Research and Reports in Urology, August 2016, Dove Medical Press

    MD lawrence i karsh